Pancreatic ductal adenocarcinoma chemoresistance:From metabolism reprogramming to novel treatment

扫码查看

原文链接

国家科技期刊平台
NETL
NSTL
万方数据

外文摘要：As pancreatic cancer(PC)is highly malignant,its patients tend to develop metastasis at an early stage and show a poor response to conventional chemotherapies.First-line chemotherapies for PC,according to current guidelines,include fluoropyrimidine-and gemcitabine-based regimens.Accumulating research on drug resistance has shown that biochemical metabolic aberrations in PC,especially those involving glycolysis and glutamine metabolism,are highly associated with chemoresistance.Additionally,lipid metabolism is a major factor in chemoresistance.However,emerging compounds that target these key metabolic pathways have the potential to overcome chemoresistance.This review summarizes how PC develops chemoresistance through aberrations in biochemical metabolism and discusses novel critical targets and pathways within cancer metabolism for new drug research.

外文关键词：

Pancreatic cancerDrug resistanceDrug developmentSignal transduction

作者：

Jingcheng Zhang、Yutong Wang、Lejunzi Wang、Lei You、Taiping Zhang

展开 >

作者单位：

Department of General Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China

Peking Union Medical College,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China

Department of Anaesthesia,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China

Clinical Immunology Centre,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China

展开 >

基金：

National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNatural Science Foundation of Beijing

项目编号：

81772639818024757192157

出版年：

2024

DOI：

10.1097/CM9.0000000000002758

中华医学杂志(英文版)

中华医学会

中华医学杂志(英文版)

CSTPCD

影响因子：0.838

ISSN：0366-6999

年,卷(期)：2024.137(4)

参考文献量85